NASDAQ:ICLR - Icon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $149.43 -0.24 (-0.16 %) (As of 09/25/2018 04:00 PM ET)Previous Close$149.67Today's Range$147.69 - $150.4652-Week Range$101.22 - $151.86Volume213,300 shsAverage Volume255,677 shsMarket Capitalization$8.13 billionP/E Ratio27.71Dividend YieldN/ABeta0.35 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland. Receive ICLR News and Ratings via Email Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNASDAQ:ICLR CUSIPN/A Webwww.iconplc.com Phone353-1291-2000 Debt Debt-to-Equity Ratio0.28 Current Ratio2.10 Quick Ratio2.10 Price-To-Earnings Trailing P/E Ratio27.71 Forward P/E Ratio24.58 P/E Growth2.15 Sales & Book Value Annual Sales$1.76 billion Price / Sales4.60 Cash Flow$6.5626 per share Price / Cash22.77 Book Value$22.02 per share Price / Book6.79 Profitability EPS (Most Recent Fiscal Year)$5.39 Net Income$281.48 million Net Margins13.69% Return on Equity26.35% Return on Assets14.60% Miscellaneous Employees13,250 Outstanding Shares54,080,000Market Cap$8.13 billion Icon (NASDAQ:ICLR) Frequently Asked Questions What is Icon's stock symbol? Icon trades on the NASDAQ under the ticker symbol "ICLR." How were Icon's earnings last quarter? Icon Plc (NASDAQ:ICLR) released its quarterly earnings data on Wednesday, July, 25th. The medical research company reported $1.31 EPS for the quarter, missing analysts' consensus estimates of $1.48 by $0.17. The medical research company earned $641.60 million during the quarter, compared to analysts' expectations of $618.64 million. Icon had a return on equity of 26.35% and a net margin of 13.69%. The business's revenue for the quarter was up 48.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.34 earnings per share. View Icon's Earnings History. When is Icon's next earnings date? Icon is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Icon. What price target have analysts set for ICLR? 8 equities research analysts have issued 12-month target prices for Icon's stock. Their predictions range from $120.00 to $157.00. On average, they expect Icon's stock price to reach $144.1250 in the next twelve months. This suggests that the stock has a possible downside of 3.6%. View Analyst Price Targets for Icon. What is the consensus analysts' recommendation for Icon? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon. Who are some of Icon's key competitors? Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and VIRALYTICS Ltd/S (VRACY). Who are Icon's key executives? Icon's management team includes the folowing people: Dr. Steven A. Cutler, CEO & Director (Age 58)Mr. Brendan Brennan, Chief Financial Officer (Age 39)Jonathan Curtain, VP of Corp. Fin. & Investor RelationsMr. Thomas O'Leary, Chief Information OfficerMr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 43) Who are Icon's major shareholders? Icon's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include WCM Investment Management CA (8.57%), Acadian Asset Management LLC (4.02%), Earnest Partners LLC (4.02%), Renaissance Technologies LLC (3.58%), Boston Partners (3.08%) and FMR LLC (2.96%). Which major investors are selling Icon stock? ICLR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Wells Fargo & Company MN, Victory Capital Management Inc., Wasatch Advisors Inc., Systematic Financial Management LP, Mckinley Capital Management LLC Delaware and Janus Henderson Group PLC. Which major investors are buying Icon stock? ICLR stock was purchased by a variety of institutional investors in the last quarter, including WCM Investment Management CA, Partner Fund Management L.P., Advisors Asset Management Inc., Redwood Investments LLC, Envestnet Asset Management Inc., Massachusetts Financial Services Co. MA, Boston Partners and Cornerstone Wealth Management LLC. How do I buy shares of Icon? Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Icon's stock price today? One share of ICLR stock can currently be purchased for approximately $149.43. How big of a company is Icon? Icon has a market capitalization of $8.13 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe. What is Icon's official website? The official website for Icon is http://www.iconplc.com. How can I contact Icon? Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000. MarketBeat Community Rating for Icon (NASDAQ ICLR)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 422 (Vote Outperform)Underperform Votes: 303 (Vote Underperform)Total Votes: 725MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/25/2018 by MarketBeat.com StaffFeatured Article: How are the companies in the S&P 500 selected?